To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
ForteBio Launches Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies
Read time: Less than a minute
ForteBio®, Inc. has announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company's Octet® instrumentation platform.
The new biosensor can enable easy-to-use and rapid kinetic characterization and screening of human IgG antibodies and other Fc-containing proteins and further broadens the menu of Octet system applications.
"Researchers in bioprocessing and cell line development who study kinetic characterization of human IgG antibodies and other proteins can now benefit from the efficiencies of ForteBio's Octet platform, which enables high-throughput, real-time, label-free detection and screening," said Christopher Silva, ForteBio's vice president of marketing.
"The innovative, new AHC biosensor enables off-the-shelf, capture-based kinetics of human IgGs or other Fc-containing proteins without the need to biotinylate. It is also designed for use in buffer or crude supernatants, and can be regenerated and reused for increased cost-efficiency," Silva said.
The new AHC biosensor leverages the Octet platform's proprietary Bio-Layer Interferometry technology to enable kinetic profiling of human IgGs against analyte in a microplate well format.
The biosensor surface can also be used to conduct ligand inhibition assays by expanding the variables that can be measured, such as blocking and unblocking analytes, affinity, and association and dissociation rates. The new AHC biosensor further expands the capabilities of the Octet platform which already supports quantitation of human IgG using Protein A.
ForteBio's Octet biosensors are configured in a standard 96-well format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
The new biosensor can enable easy-to-use and rapid kinetic characterization and screening of human IgG antibodies and other Fc-containing proteins and further broadens the menu of Octet system applications.
"Researchers in bioprocessing and cell line development who study kinetic characterization of human IgG antibodies and other proteins can now benefit from the efficiencies of ForteBio's Octet platform, which enables high-throughput, real-time, label-free detection and screening," said Christopher Silva, ForteBio's vice president of marketing.
"The innovative, new AHC biosensor enables off-the-shelf, capture-based kinetics of human IgGs or other Fc-containing proteins without the need to biotinylate. It is also designed for use in buffer or crude supernatants, and can be regenerated and reused for increased cost-efficiency," Silva said.
The new AHC biosensor leverages the Octet platform's proprietary Bio-Layer Interferometry technology to enable kinetic profiling of human IgGs against analyte in a microplate well format.
The biosensor surface can also be used to conduct ligand inhibition assays by expanding the variables that can be measured, such as blocking and unblocking analytes, affinity, and association and dissociation rates. The new AHC biosensor further expands the capabilities of the Octet platform which already supports quantitation of human IgG using Protein A.
ForteBio's Octet biosensors are configured in a standard 96-well format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
